On the Record · DR Reddys Laboratories
DR Reddys Laboratories competitors, on the record
The companies DR Reddys Laboratories itself names as competitors in its annual reports, 2024 to 2026, each with the sentence it appears in and the filing it came from.
Who DR Reddys Laboratories names
| Company | Named in |
|---|---|
| Accord Healthcare Limited | 2026 |
| Apotex | 2026 |
| Cipla Limited | 2026 |
| Divis Laboratories Limited | 2026 |
| Granules | 2026 |
| Hikma Pharmaceuticals plc | 2026 |
| Kenvue | 2026 |
| KRKA Pharma Limited | 2026 |
| Lonza Group | 2026 |
| Perrigo | 2026 |
| Stada Arzneimittel AG | 2026 |
| Syngene International Ltd. | 2026 |
| Teva | 2026 |
| Viatris Inc. | 2026 |
| Zentiva Pharma GmbH | 2026 |
| Zhejiang Huahai | 2026 |
In its own words
Accord Healthcare Limited
Word for word“In Italy, Spain and France, we compete with companies such as, Zentiva, Ever Pharma, Medac, Teva and Accord Healthcare Limited (an affiliate of Intas Pharmaceuticals Ltd.), each of which has a well-established presence in the hospital segment of these countries.” 20-F for 2026
Apotex, Granules, Perrigo
Word for word“In the store brand market, we compete directly with companies, such as Perrigo, Apotex, Aurobindo, Sun Pharma and Granules that sell store brand OTC products.” 20-F for 2026
Cipla Limited
Word for word“Our competitors in the Indian market include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Abbott India Limited, Lupin Limited, Aristo Pharma Limited, Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Torrent Pharmaceuticals Limited, Macleods Pharma and Emcure Pharmaceuticals Limited.” 20-F for 2026
Divis Laboratories Limited
Word for word“Our main competitors in this segment are Divis Laboratories Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, Sun Pharmaceutical Industries Limited and MSN Laboratories Limited, all based or operating in India.” 20-F for 2026
Hikma Pharmaceuticals plc, Teva, Viatris Inc.
Word for word“Our major competitors in the United States include Teva, Viatris Inc., Sandoz, Sun Pharmaceuticals Limited and Hikma Pharmaceuticals plc.” 20-F for 2026
Kenvue
Word for word“The NRT category is relatively concentrated, with key competitors including Kenvue’s Nicorette product and Perrigo’s NiQuitin product, alongside private label offerings.” 20-F for 2026
KRKA Pharma Limited
Word for word“Our principal competitors in the Russian market include Berlin-Chemie/Menarini Pharma GmbH, KRKA Pharma Limited, Teva Pharmaceutical Industries Limited, Lek-Sandoz Pharmaceuticals and Zao Ranbaxy (an affiliate of Sun Pharmaceutical Industries Limited).” 20-F for 2026
Lonza Group
Word for word“Key competitors from outside India include Lonza Group, Patheon Inc., Catalent Inc., Cambrex Inc., and WuXi Apptec.” 20-F for 2026
Stada Arzneimittel AG, Zentiva Pharma GmbH
Word for word“Our key competitors within the German generics market include Sandoz International GmbH, Teva Pharmaceutical Industries Limited (“Teva”), Zentiva Pharma GmbH and Stada Arzneimittel AG.” 20-F for 2026
Syngene International Ltd.
Word for word“Key competitors in India include Syngene International Ltd., Aragen Life Sciences, Sai Life Sciences and Piramal Pharma Ltd.” 20-F for 2026
Zhejiang Huahai
Word for word“In addition, we experience competition from European and Chinese manufacturers such as Zhejiang Huahai, Tianyu, as well as from Teva Pharmaceuticals Industries Limited, based in Israel.” 20-F for 2026
Read from DR Reddys Laboratories’s annual reports (20-F for 2026, 20-F for 2025, 20-F for 2024) and the financial data it files with the SEC, as of 2026-05-29. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.